Treatment of osteoporosis

A compound of formula (I)

• wherein:
• R1 represents hydrogen, halogen, cyano, trifluoromethyl, nitro, —ORa, SRa, SORa, —SO2Ra, —SO2NRaRb, —NRaRb, —NRaCORb, —NRaCO2Rb, —CORa, —CO2Ra, —CONRaRb, or a hydrocarbon group comprising a straight chain, branched or cyclic group each containing up to 18 carbon atoms, or a heterocyclic group containing up to 18 carbon atoms and at least one heteroatom;
• R2 represents, independently at each occurrence, hydrogen, halogen, cyano, trifluoromethyl, nitro, —ORa, SRa, SORa, —SO2Ra, —SO2NRaRb, —NRaRb, —NRaCORb, —NRaCO2Rb, —CORa, —CO2Ra, —CONRaRb, or a hydrocarbon group comprising a straight chain, branched or cyclic group each containing up to 18 carbon atoms, or a heterocyclic group containing up to 18 carbon atoms and at least one heteroatom;
• R3 represents a hydrocarbon group comprising a straight chained, branched or cyclic group each containing up to 18 carbon atoms, and being substituted by at least one moiety including a —CO2Ra substituent;
• wherein Ra and Rb independently represent, at each occurrence, hydrogen, or a hydrocarbon group comprising a straight chained, branched or cyclic group each containing up to 18 carbon atoms, or a heterocyclic group containing up to 18 carbon atoms and at least one heteroatom;
• and
• n is 0, 1, 2, 3 or 4;
• or a pharmaceutically acceptable solvate salt or prodrug thereof;
• for use in the treatment of osteoporosis and/or osteopenia.